drugset / Trial / NCT00012298
Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
Phase I/II trial to study the effectiveness of combining radiolabeled monoclonal antibody therapy and rituximab with and without filgrastim and interleukin-11 in treating patients who have relapsed or refractory non-Hodgkin's lymphoma. Radiolabeled monoclonal antibodies can locate cancer cells and deliver cancer-killing substances to them without harming normal cells. Biological therapies such as filgrastim and interleukin-11 use different ways to stimulate the immune system and stop cancer cells from growing.
Timeline
- Start
- 2001-04
- Primary completion
- 2010-04
- Completion
- 2010-04
Outcome
Outcome not reported
Stopped: “Trial completed prematurely.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 90Y-ibritumomab tiuxetan | Other / unclassified | — | Intravenous |
| Subject | Indium In-111 Ibritumomab Tiuxetan | Monoclonal antibody | — | Intravenous |
| Subject | Oprelvekin | Protein / enzyme biologic | — | — |
| Subject | filgrastim | Protein / enzyme biologic | — | Subcutaneous |
| Background | Rituximab | Monoclonal antibody | — | Intravenous |